Open AccessRechallenge with Multi-Targeted Tyrosine Kinase Inhibitors in Patients with Advanced Soft Tissue Sarcoma: A Single-Center Experience
Author(s) -
Jie Liu,
Yao Deng,
Xin Wu,
Yu Jiang
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s300430
Subject(s) - medicine , pazopanib , apatinib , regorafenib , soft tissue sarcoma , sarcoma , oncology , adverse effect , tyrosine kinase inhibitor , soft tissue , cabozantinib , gist , targeted therapy , imatinib , progression free survival , chemotherapy , surgery , sunitinib , pathology , cancer , stromal cell , colorectal cancer , myeloid leukemia
Chemotherapy and multi-targeted tyrosine kinase inhibitors (TKI) are important treatments for advanced soft tissue sarcomas, but the following treatment remains unclear after the failure of these drugs. This retrospective study investigated the efficacy and safety of multi-targeted TKI rechallenge in patients with advanced soft tissue sarcoma after the failure of previous TKI treatment.